Abstract:Linda Nguyen, Cynthia Wang Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA Correspondence: Linda Nguyen, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA, Tel +1-214-645-0136, Fax +1-214-645-8238, Email Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most recognized form of autoimmune encephalitis. It is characterized by a constellation of neurologic and psychiatric features along with positive NMDAR antibody, which is more sensitive and specific in CSF than serum. All patients should be screened at least once for neoplasm, with ovarian teratoma being found in most tumor-related cases. In the acute phase, first-line immunotherapy, often a combination of high-dose steroids, immunoglobulins, and/or plasma exchange, is strongly recommended. When first-line therapy fails, escalation to second-line immunotherapy, particularly rituximab, can further improve outcomes and prevent relapses. In refractory cases, additional complementary immunotherapies, such as cyclophosphamide, bortezomib and/or tocilizumab may be considered. Relapses occur in 10– 30% of cases, mostly within the first two years from onset. Individuals should be followed up to determine if chronic maintenance therapy is required. Keywords: anti-NMDAR encephalitis, clinical features, immunotherapies, treatment options Autoimmune encephalitis (AE) refers to an increasingly recognized group of non-infectious, immune-mediated inflammatory brain disorders. Presently, the most recognized is anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, resulting from production of autoantibodies to the neuronal NMDAR NR1 subunit. These autoantibodies are thought to cause internalization of the NMDAR, along with severe impairment of synaptic plasticity and NMDAR network dysfunction. 1 Patients with this disorder present with an acute to subacute decline in cognitive function and neuropsychiatric symptoms, often accompanied by new onset seizures, movement disorder, disturbed sleep, and encephalopathy. It was initially classified as a paraneoplastic syndrome, occurring in young females in association with an ovarian teratoma. 2 However, it can occur following other stimuli such as infection and impact men and children. 3 Despite the rapidly growing literature on this disorder following its original characterization in 2007, 2 there have been no published randomized clinical trials to date. In this review, we will discuss the epidemiology, clinical presentation, and diagnostic and management strategies for anti-NMDAR encephalitis. While the exact incidence of anti-NMDAR encephalitis is unknown, it is currently considered the most common form of AE. In an early population-based study, Dubey et al reported that the incidence of AE in Olmsted County, Minnesota increased over time from 0.4/100,000 person-years (1995–2005) to 1.2/100,000 person-years (2006–2015). 4 The prevalence of AE on January 1, 2014 was 13.7/100,000, which was comparable to all infectious encephalitides combined (11.5/100,000). The prevalence of anti-NMDAR encephalitis cases was 0.6/100,000. 4 Similarly, the incidence of anti-NMDAR encephalitis in Denmark increased from 2009 to 2018, with the lowest rates in 2009/2010 (0 and 0.036/100,000 person-years) and highest rates in 2017/2018 (0.123 and 0.173/100,000 person-years). 5 In Fall 2007, the California Encephalitis Project began identifying cases of anti-NMDAR encephalitis and found that anti-NMDAR encephalitis was the leading form of encephalitis from 2007 to 2011 and occurred about four times as frequently as herpes simplex virus 1 and about six times as frequently as West Nile virus or varicella zoster virus. 6 It also exceeded those of enteroviral encephalitis, comprising 41% compared to 38% of all cases. 6 In a retrospective study of 505 young patients admitted to the intensive care unit (ICU) at a single center in Germany with encephalitis of unknown etiology from June 2004 to 2009, anti-NMDAR encephalitis represented 1% of the admissions. 7 With increasing awareness and testing, these numbers will likely continue to rise. In a recent study involving over 40,000 patients tested at the Mayo Clinic Neuroimmunology Laboratory between January 2018 and December 2019, Kunchok et al reported 3.6% serum and 4.2% cerebral spinal fluid (CSF) analyses were positive for AE antibodies in adults and 4.4% serum and 5.5% CSF analyses were positive in children. 8 Of the positive cases, anti-NMDAR antibodies were most commonly observed: 24.6% (adult serum), 53.1% (children serum), 39.7% (adult CSF), and 88.1% (children CSF). 8 Female sex and younger age were associated with higher rates of NMDAR detection (odds ratio [OR] 1.32, P<0.01 -Abstract Truncated-

Diverse anti-NMDAR autoantibodies from individuals with encephalitis

Structural and functional mechanisms of anti-NMDAR autoimmune encephalitis

NMDA Receptor Autoantibodies in Autoimmune Encephalitis Cause a Subunit-Specific Nanoscale Redistribution of NMDA Receptors

Converging synaptic and network dysfunctions in distinct autoimmune encephalitis

Anti-NMDAR antibodies, the blood–brain barrier, and anti-NMDAR encephalitis

Autoimmune N-methyl-D-aspartate receptor encephalitis is a differential diagnosis of infectious encephalitis

How autoimmune antibodies kindle a firestorm in the brain

Specific and Polyfunctional T Cell Response Against N-Methyl-D-aspartate Receptor in an Autoantibody-Mediated Encephalitis Model

Single‐cell RNA sequencing reveals diverse B cell phenotypes in patients with anti‐NMDAR encephalitis

Comprehensive B-Cell Immune Repertoire Analysis of Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis

Human NMDAR autoantibodies disrupt excitatory-inhibitory balance, leading to hippocampal network hypersynchrony

A case of GFAP-IgG positivity followed by anti-NMDAR encephalitis

Autoantibodies Detection in Anti-N-methyl-d-aspartate Receptor Encephalitis.

Anti-NMDAR encephalitis with GFAPα IgG: a case report

Clinicopathological Characteristics of Dysplastic Teratomous Neuroglia with Anti-N-methyl-d-aspartate Receptor Encephalitis.

Anti-NMDA Receptor Autoimmune Encephalitis: Diagnosis and Management Strategies

Study of B Cell Repertoire in Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Autoimmune Epilepsy - Novel Multidisciplinary Analysis, Discoveries and Insights

Immuno-Pharmacological Characterization of Presynaptic GluN3A-Containing NMDA Autoreceptors: Relevance to Anti-NMDA Receptor Autoimmune Diseases

Single-cell analyses of CSF and PBMCs from anti-NMDAR encephalitis patients reveals distinct characteristics of T cell subpopulations

Positive Allosteric Modulation of NMDARs Prevents the Altered Surface Dynamics Caused by Patients' Antibodies